The Global Cancer
Biomarkers Market, by Biomarker Type (Protein Biomarkers, Genetic
Biomarkers, and Others), By Cancer Type (Breast Cancer, Lung Cancer, Prostate
Cancer, Kidney Cancer, Liver Cancer, and Others), by End User (Hospitals,
Academic and Cancer Research Institutes, Ambulatory Surgical Centers, and
Diagnostic Laboratories), was valued US$ 33.7 billion in 2017 and is projected
to exhibit a CAGR of 14.2% over the forecast period (2017–2025).
Growing prevalence and incidence
of various types of cancer coupled with increasing need for early diagnosis of
cancers are the major factors driving growth of global cancer biomarkers market
over the forecast period. Continuous research and development and technology
advancements in cancer biomarkers had led to introduction of better and
affordable biomarkers in the field of clinical diagnosis. For instance,
according to the data published in Cell Metabolism Journal, in March 2018, a
team of Australian researchers found a unique metabolic marker, which can detect
adenocarcinomas, a form of lung cancer. These metabolic biomarkers respond to
immunotherapies and offers simple, non-invasive blood test for early detection
of lung cancer.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/175
Browse 35 Market Data Tables and
33 Figures spread through 160 Pages and in-depth TOC on "Cancer Biomarkers
Market, by Biomarker Type (Protein Biomarkers, Genetic Biomarkers and Other
Cancer Biomarkers), By Cancer Type (Breast Cancer, Lung Cancer, Prostate
Cancer, Kidney Cancer, Liver Cancer and Other Cancers), by End User (Hospitals,
Academic and Cancer Research Institutes, Ambulatory Surgical Centers,
Diagnostic Laboratories) - Global Forecast to 2025"
In February 2018, researchers at
Georgetown-Lombardi Comprehensive Cancer Center, identified biomarkers, which
can use liquid biopsies to predict response to cancer treatment and help in
identifying increasingly specific subsets of GI cancers to make treatment
decisions. According to the data published in the European Journal of Breast
Health, in October 2017, body fluid tests can be used for early detection of
new or recurrent breast cancer. This new approach includes tissue testing and
body fluid analysis of individuals diagnosed with breast cancer, for more
effective cancer treatment. Moreover, manufacturers are focusing on developing
new cancer biomarkers, which would aid in early diagnosis of cancers and are
used for oncology research studies. For instance, in November 2016, Oxford
Cancer Biomarkers Ltd. introduced ColoTox test for predicting risk of toxicity
with cancer chemotherapy tests. In December 2015, Olink Bioscience introduced
Proseek Multiplex Oncology II96x96: 92 human protein biomarker panel for
oncology research.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/cancer-biomarkers-market-175
Key takeaways of the cancer
biomarkers market:
The global cancer biomarkers
market is expected to expand at a CAGR of 14.2% during the forecast period
(2017–2025), owing to increasing prevalence and incidence of cancer and growing
demand for early diagnosis of cancer. For instance, according to the Cancer
Atlas: 2017, there were an estimated 14.1 million new cancer cases in 2012.
Moreover, India, China and other East and Central Asian countries accounted for
nearly half of world’s new cancer cases and deaths, in 2017. In addition,
according to the same source, by 2025, there will be an estimated 19.3 million
new cancer cases and 11.4 million cancer deaths, in less developed regions.
Protein biomarkers segment holds
a major share in the market, owing to its extensive use in analyzing protein
concentration in blood, tissue, urine, and other body fluids for early cancer
detection.
Liver cancer segment holds
largest revenue share in the market, owing to increasing number of liver cancer
biomarkers in the market and their ability for efficient diagnosis of early
liver cancer
Among end users, diagnostic
laboratories segment holds the largest market share, owing to its ability to
provide advanced laboratory testing and research services for cancer research
to researchers and oncologist.
Some of the major players
involved in global cancer biomarkers market include BioMerieux S.A., Bard1 Life
Sciences Limited, Bio-Rad Laboratories, Abbott Laboratories, Becton, Dickinson
and Company, Merck & Co., Inc., Qiagen N.V., and Thermo Fisher Scientific
Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/175
About
Coherent Market Insights:
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment